MedPath

Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung

Active, not recruiting
Conditions
Lung Cancer (NSCLC)
Lung Cancer (SCLC)
Registration Number
NCT07202260
Lead Sponsor
The Christie NHS Foundation Trust
Brief Summary

This study focuses on improving care for people with lung cancer who face unusual or complex treatment situations.

Detailed Description

By studying detailed patient data, researchers aim to find the best ways to treat these patients while reducing short- and long-term side effects. The findings will help refine radiotherapy treatments, ensuring they are as safe and effective as possible. Additionally, the results will provide doctors with better information to help patients understand the potential risks and benefits of their treatment options.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria

Complex patients with lung cancer undergoing radiotherapy in one of the following groups;

  • Rare histology
  • Disease invading vascular structures
  • Co-existing interstitial lung disease (ILD)
  • Radical re-irradiation
  • Oligopersistent/oligoprogressive disease on immunotherapy or targeted therapies.
Exclusion Criteria
  • Include patients with stage IV disease who are receiving non-curative intent radiotherapy
  • There are no exclusion criteria relating to upper age limit or comorbidities.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Acute and late toxicity2 years

\- Acute (\<90 days post radiotherapy) and late (\> 90 days post radiotherapy) toxicity according to common terminology criteria for adverse events (CTCAE) V5.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

The Christie NHS Foundation Trust

🇬🇧

Withington, Greater Manchester, United Kingdom

The Christie NHS Foundation Trust
🇬🇧Withington, Greater Manchester, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.